By Business/Source
Currency:USD
2025/Q3
Stock NameRevenueRatio
Developing and commercializing highly differentiated therapies that have a meaningful impact26M100.00%
By Country/Region
Currency:USD
2024/FY
Stock NameRevenueRatio
United States258M100.00%